Orion Portfolio Solutions LLC Purchases New Shares in Grifols, S.A. (NASDAQ:GRFS)

Orion Portfolio Solutions LLC acquired a new position in Grifols, S.A. (NASDAQ:GRFS) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 15,954 shares of the biotechnology company’s stock, valued at approximately $119,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares during the period. HighTower Advisors LLC boosted its stake in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,546 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Grifols by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 1,657 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Grifols by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 2,403 shares during the last quarter. Finally, R Squared Ltd bought a new stake in shares of Grifols in the 4th quarter worth approximately $28,000.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley began coverage on Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Stock Performance

Shares of GRFS stock opened at $6.76 on Friday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of 5.78 and a beta of 0.41. Grifols, S.A. has a one year low of $5.79 and a one year high of $9.96. The company’s 50-day moving average is $7.49 and its 200 day moving average is $7.88.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.